Nina Y Lai, PA
Physician Assistant · Santa Rosa
- Medicare standing
- 2 flags on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 10 years
- Graduated 2016
On the public record
- California licence: Surrendered
- 2 Medical Board actions on record
Offices
2 locations · Redwood Fam Dermatology Medical Associates - A Medical Corporation · 18 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Nina Y Lai’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C54213 · Surrendered
Licence status: Surrendered · since 2010 · Tulane University School of Medicine. Board flags: Admin Action By Other State/Fed Gov'T.
Licensee has surrendered his or her license to resolve a disciplinary or licensing action. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
Public record actions
| 2017-08-22 | Board disciplineDiscipline | Surrender of license. · 8002016026681 |
| 2017-06-26 | Action in another state or by a federal agencyDiscipline | Effective 09/29/16 florida medical license is restricted from controlled substance privileges in stated schedules. effective 06/26/17 interim conditions established, assessed a fine, issued a letter of concern and suspended. · Florida board of medicine |
Original Medicare doctor bills
$195,272
Medicare paid this office $195,272 for 936 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 444 | $30,649 | $59 |
| Return visit (30+ min) | 236 | $24,555 | $81 |
| Biopsy of related skin growth, first growth | 317 | $23,348 | $66 |
| Destruction of precancer skin growth, 1 growth | 423 | $18,518 | $36 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 52 | $12,932 | $219 |
See all 22 services
| Short return visit (20+ min) | 444 | $30,649 | $59 |
| Return visit (30+ min) | 236 | $24,555 | $81 |
| Biopsy of related skin growth, first growth | 317 | $23,348 | $66 |
| Destruction of precancer skin growth, 1 growth | 423 | $18,518 | $36 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 52 | $12,932 | $219 |
| Destruction of precancer skin growth, 15 or more growths | 87 | $11,334 | $113 |
| Destruction of skin growth, 1-14 growths | 121 | $10,796 | $74 |
| Destruction of precancer skin growth, 2-14 growths | 344 | $10,763 | $5 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 12 | $6,193 | None |
| Biopsy of related skin growth, each additional growth | 102 | $6,161 | $36 |
| New patient visit (45+ min) | 55 | $4,857 | $88 |
| New patient visit (30+ min) | 89 | $4,798 | $54 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 45 | $4,763 | $93 |
| Short return visit | 96 | $3,714 | $37 |
| Application of light to destroy precancer skin growth | 12 | $1,901 | $106 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 18 | $1,753 | $97 |
| Punch biopsy, first skin growth | 19 | $1,535 | $81 |
| Biopsy of ear | 26 | $1,327 | $51 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 11 | $1,159 | $105 |
| New patient visit (15+ min) | 26 | $859 | $33 |
| Injection into skin growth, 1-7 growths | 16 | $832 | $33 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 14 | $16 | None |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 32 | More than 81% of doctors who do this |
| Removal of skin lesions | 760 | More than 91% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 285 | More than 90% of doctors who do this |
Procedures year by year
| Procedure | 2023 | 2024 |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,099 | 2,174 |
| Destruction of precancer skin growth, 1 growth | 306 | 510 |
| Biopsy of related skin growth, first growth | 275 | 354 |
| Biopsy of related skin growth, each additional growth | 121 | 169 |
| Destruction of skin growth, 1-14 growths | 121 | 146 |
| Destruction of precancer skin growth, 15 or more growths | 36 | 100 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
936 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 12% · Women 56% · Also on Medicaid 20% · Health risk score 1.03. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 59% · Coronary heart disease 23% · Diabetes 18% · Atrial fibrillation 17% · Depression 16% · Chronic kidney disease 15% · Cancer 11% · COPD 11% · Heart failure 10% · Stroke 6% · Dementia 3%.
The office billed $618,781, Medicare allowed $275,744 and paid $195,272; for 5,014 services of 54 kinds; $6,209 of it was for drugs given in the office and $189,063 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 936 | 5,014 | 75 | 1.03 | $618,781 | $195,272 |
| 2023 | 607 | 3,017 | 74 | 1.06 | $394,954 | $128,592 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Biopsy of related skin growth, first growth | 238 | $18,525 | $67 |
| Short return visit (20+ min) | 237 | $17,535 | $62 |
| Return visit (30+ min) | 126 | $14,264 | $85 |
| Destruction of precancer skin growth, 1 growth | 232 | $10,970 | $36 |
| Destruction of skin growth, 1-14 growths | 98 | $10,020 | $83 |
| New patient visit (30+ min) | 115 | $8,106 | $70 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 21 | $6,395 | $228 |
| Destruction of precancer skin growth, 2-14 growths | 177 | $5,594 | $5 |
| New patient visit (45+ min) | 51 | $5,320 | $104 |
| Biopsy of related skin growth, each additional growth | 78 | $4,565 | $38 |
| Destruction of precancer skin growth, 15 or more growths | 35 | $4,494 | $125 |
| Short return visit | 58 | $2,560 | $40 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 17 | $2,157 | $108 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 16 | $1,909 | $119 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 11 | $1,590 | $106 |
| Biopsy of ear | 24 | $1,276 | $49 |
| New patient visit (15+ min) | 33 | $1,239 | $38 |
| Injection into skin growth, 1-7 growths | 19 | $1,022 | $32 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $21 | None |
Medicaid work
$6,562 in 2024
Medicaid paid $6,562 for 146 billed services this clinician did in 2024, up to 36 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 84 | $4,865 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion | 14 | $987 |
| Short return visit (20+ min) | 48 | $710 |
| 2024 | 146 | 3 | 36 | $6,562 |
| 2021 | 150 | 3 | 22 | $59,875 |
| 2020 | 45 | 1 | 21 | $16,285 |
See the largest Medicaid services in earlier years
2021
| Clinic visit/encounter, all-inclusive | 101 | $59,875 |
| Short return visit (20+ min) | 25 | $0 |
| Return visit (30+ min) | 24 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 45 | $16,285 |
Drugs they prescribed that Part D paid
$668,690
Pharmacies billed $668,690 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 862) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
766 generic and 96 brand-name prescriptions · $668,690 in drug cost · 69 antibiotic prescriptions to 40 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Skyrizi | 11 | $229,862 | $20,897 |
| Dupixent | 41 | $188,631 | $4,601 |
| Cosentyx Sensoready (2 Pens) | 19 | $137,575 | $7,241 |
| Tacrolimus | 13 | $2,967 | $228 |
| Fluocinonide | 60 | $2,483 | $41 |
See all 17 drugs
| Skyrizi | 11 | $229,862 | $20,897 |
| Dupixent | 41 | $188,631 | $4,601 |
| Cosentyx Sensoready (2 Pens) | 19 | $137,575 | $7,241 |
| Tacrolimus | 13 | $2,967 | $228 |
| Fluocinonide | 60 | $2,483 | $41 |
| Ketoconazole | 194 | $2,431 | $13 |
| Metronidazole | 33 | $2,096 | $64 |
| Clobetasol Propionate | 43 | $1,974 | $46 |
| Fluocinolone Acetonide | 24 | $1,168 | $49 |
| Fluorouracil | 13 | $952 | $73 |
| Triamcinolone Acetonide | 110 | $795 | $7 |
| Ciclopirox | 20 | $705 | $35 |
| Doxycycline Monohydrate | 39 | $641 | $16 |
| Hydrocortisone | 92 | $439 | $5 |
| Cephalexin | 17 | $161 | $9 |
| Doxycycline Hyclate | 11 | $147 | $13 |
| Mupirocin | 13 | $90 | $7 |
Year by year
| 2024 | 862 | 336 | 0% (0) | 11% | $668,690 |
| 2023 | 438 | 190 | 0% (0) | 15% | $347,153 |
| 2022 | 136 | 87 | 0% (0) | 16% | $163,976 |
| 2021 | 191 | 120 | 0% (0) | None | $3,653 |
| 2020 | 136 | 82 | 0% (0) | 17% | $4,764 |
| 2019 | 190 | 119 | None | None | $7,830 |
| 2018 | 198 | 116 | None | None | $7,146 |
| 2017 | 128 | 88 | 9% (11) | None | $2,997 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Dupixent | 34 | $128,501 | $3,779 |
| Clobetasol Propionate | 36 | $4,116 | $114 |
| Fluocinolone Acetonide | 18 | $1,814 | $101 |
| Fluocinonide | 25 | $1,283 | $51 |
| Ketoconazole | 69 | $1,109 | $16 |
| Cephalexin | 17 | $573 | $34 |
| Triamcinolone Acetonide | 59 | $453 | $8 |
| Hydrocortisone | 50 | $320 | $6 |
2022: 1 drug
| Triamcinolone Acetonide | 23 | $250 | $11 |
2021: 2 drugs
| Cephalexin | 30 | $201 | $7 |
| Sulfamethoxazole-Trimethoprim | 11 | $37 | $3 |
2020: 1 drug
| Cephalexin | 14 | $68 | $5 |
2019: 3 drugs
| Ventolin Hfa | 12 | $679 | $57 |
| Cephalexin | 14 | $124 | $9 |
| Sulfamethoxazole-Trimethoprim | 14 | $72 | $5 |
2018: 1 drug
| Ibuprofen | 16 | $61 | $4 |
2017: 1 drug
| Ibuprofen | 13 | $55 | $4 |
Money from drug and device companies
$1,988 in 2025
| 2025 | 16 | 97 | None | $1,988 |
| 2024 | 19 | 123 | None | $2,823 |
| 2023 | 13 | 78 | None | $1,685 |
| 2022 | 8 | 22 | None | $550 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $243 | 16 payments
|
| Arcutis Biotherapeutics | Zoryve | $238 | 6 payments
|
| Ucb | Bimzelx | $216 | 13 payments
|
| Janssen Biotech | Tremfya | $205 | 10 payments
|
| Lilly USA | Taltz | $194 | 7 payments
|
| Novartis Pharmaceuticals | Cosentyx | $162 | 9 payments
|
See all 97 published payments
| Abbvie | Meals · 2025-11-26 | Skyrizi | $7 |
| LEO Pharma | Meals · 2025-10-10 | Adbry | $21 |
| Ucb | Meals · 2025-09-12 | Bimzelx | $12 |
| Arcutis Biotherapeutics | Meals · 2025-09-10 | Zoryve | $15 |
| Janssen Biotech | Meals · 2025-09-09 | Tremfya | $26 |
| Genzyme | Meals · 2025-09-03 | Dupixent | $22 |
| Galderma Laboratories L.P. | Meals · 2025-08-27 | Nemluvio | $25 |
| Novartis Pharmaceuticals | Meals · 2025-08-25 | Cosentyx | $8 |
| Ucb | Meals · 2025-08-15 | Bimzelx | $15 |
| Ucb | Meals · 2025-08-15 | Bimzelx | $15 |
| Incyte | Meals · 2025-08-14 | Opzelura | $23 |
| Lilly USA | Meals · 2025-08-12 | Taltz | $25 |
| Abbvie | Meals · 2025-08-05 | Rinvoq | $15 |
| Arcutis Biotherapeutics | Meals · 2025-08-05 | Zoryve | $28 |
| Galderma Laboratories L.P. | Meals · 2025-07-30 | Nemluvio | $28 |
| LEO Pharma | Meals · 2025-07-29 | Adbry | $20 |
| Ucb | Meals · 2025-07-24 | Bimzelx | $15 |
| Incyte | Meals · 2025-07-22 | Opzelura | $17 |
| Pfizer | Meals · 2025-07-18 | Cibinqo | $26 |
| Abbvie | Meals · 2025-07-16 | Rinvoq | $11 |
| Lilly USA | Meals · 2025-07-15 | Ebglyss | $32 |
| Regeneron Healthcare Solutions | Meals · 2025-07-14 | Dupixent | $23 |
| Ucb | Meals · 2025-07-11 | Bimzelx | $25 |
| Pfizer | Meals · 2025-07-11 | Cibinqo | $19 |
| Janssen Biotech | Meals · 2025-07-08 | Tremfya | $24 |
| Pfizer | Meals · 2025-07-02 | Cibinqo | $11 |
| Abbvie | Meals · 2025-06-17 | Skyrizi | $20 |
| Ucb | Meals · 2025-06-13 | Bimzelx | $25 |
| Incyte | Meals · 2025-06-13 | Opzelura | $24 |
| Lilly USA | Meals · 2025-06-11 | Ebglyss | $30 |
| Novartis Pharmaceuticals | Meals · 2025-06-11 | None | $23 |
| Pfizer | Meals · 2025-06-06 | Cibinqo | $7 |
| Janssen Biotech | Meals · 2025-06-05 | Tremfya | $28 |
| Galderma Laboratories L.P. | Meals · 2025-06-04 | Nemluvio | $22 |
| Pfizer | Meals · 2025-05-30 | Cibinqo | $14 |
| Ucb | Meals · 2025-05-29 | Bimzelx | $19 |
| Lilly USA | Meals · 2025-05-28 | Taltz | $23 |
| Genzyme | Meals · 2025-05-28 | Dupixent | $21 |
| Pfizer | Meals · 2025-05-24 | Cibinqo | $15 |
| Abbvie | Meals · 2025-05-21 | Skyrizi | $19 |
| Abbvie | Meals · 2025-05-17 | Rinvoq | $7 |
| Abbvie | Meals · 2025-05-17 | Rinvoq | $4 |
| Abbvie | Meals · 2025-05-17 | Rinvoq | $7 |
| Arcutis Biotherapeutics | Meals · 2025-05-14 | Zoryve | $8 |
| Janssen Biotech | Meals · 2025-05-13 | Tremfya | $26 |
| Ucb | Meals · 2025-05-09 | Bimzelx | $14 |
| Novartis Pharmaceuticals | Meals · 2025-05-07 | Cosentyx | $30 |
| Abbvie | Meals · 2025-05-05 | Skyrizi | $7 |
| Pfizer | Meals · 2025-05-01 | Cibinqo | $14 |
| Abbvie | Meals · 2025-04-29 | Skyrizi | $19 |
| LEO Pharma | Meals · 2025-04-25 | Adbry | $24 |
| Novartis Pharmaceuticals | Meals · 2025-04-23 | None | $77 |
| Almirall | Meals · 2025-04-22 | Klisyri | $17 |
| Regeneron Healthcare Solutions | Meals · 2025-04-16 | Dupixent | $24 |
| Galderma Laboratories L.P. | Meals · 2025-04-16 | Nemluvio | $12 |
| Ucb | Meals · 2025-04-14 | Bimzelx | $1 |
| Ucb | Meals · 2025-04-12 | Bimzelx | $15 |
| Pfizer | Meals · 2025-04-11 | Cibinqo | $18 |
| Regeneron Healthcare Solutions | Meals · 2025-04-09 | Libtayo | $38 |
| Abbvie | Meals · 2025-04-04 | Rinvoq | $12 |
| LEO Pharma | Meals · 2025-04-04 | Adbry | $20 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-03-28 | Jublia | $24 |
| Ucb | Meals · 2025-03-28 | Bimzelx | $29 |
| Galderma Laboratories L.P. | Meals · 2025-03-26 | Nemluvio | $19 |
| Arcutis Biotherapeutics | Meals · 2025-03-25 | Zoryve | $19 |
| Abbvie | Meals · 2025-03-19 | Skyrizi | $23 |
| Janssen Biotech | Meals · 2025-03-18 | Tremfya | $12 |
| Lilly USA | Meals · 2025-03-18 | Taltz | $24 |
| Janssen Biotech | Meals · 2025-03-10 | Tremfya | $4 |
| Janssen Biotech | Meals · 2025-03-10 | Tremfya | $21 |
| Pfizer | Meals · 2025-03-07 | Cibinqo | $17 |
| Ucb | Meals · 2025-03-05 | Bimzelx | $18 |
| Organon | Meals · 2025-02-28 | Vtama | $29 |
| Abbvie | Meals · 2025-02-26 | Skyrizi | $21 |
| Galderma Laboratories L.P. | Meals · 2025-02-24 | Nemluvio | $39 |
| Novartis Pharmaceuticals | Meals · 2025-02-21 | Cosentyx | $5 |
| Novartis Pharmaceuticals | Meals · 2025-02-21 | Cosentyx | $8 |
| Abbvie | Meals · 2025-02-21 | Skyrizi | $19 |
| Arcutis Biotherapeutics | Meals · 2025-02-21 | Zoryve | $146 |
| Lilly USA | Meals · 2025-02-18 | Taltz | $27 |
| Pfizer | Meals · 2025-02-14 | Cibinqo | $10 |
| Pfizer | Education · 2025-02-14 | Litfulo | $2 |
| Arcutis Biotherapeutics | Meals · 2025-02-12 | Zoryve | $22 |
| Janssen Biotech | Meals · 2025-02-11 | Tremfya | $24 |
| LEO Pharma | Meals · 2025-02-07 | Adbry | $24 |
| Janssen Biotech | Meals · 2025-02-05 | Tremfya | $18 |
| Genzyme | Meals · 2025-02-04 | Dupixent | $24 |
| Abbvie | Meals · 2025-01-24 | Rinvoq | $21 |
| Abbvie | Meals · 2025-01-22 | Skyrizi | $30 |
| Lilly USA | Meals · 2025-01-21 | Taltz | $33 |
| Ucb | Meals · 2025-01-17 | Bimzelx | $15 |
| Regeneron Healthcare Solutions | Meals · 2025-01-15 | Dupixent | $19 |
| Janssen Biotech | Meals · 2025-01-14 | Tremfya | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-10 | Sotyktu | $19 |
| Novartis Pharmaceuticals | Meals · 2025-01-07 | Cosentyx | $4 |
| Novartis Pharmaceuticals | Meals · 2025-01-07 | Cosentyx | $3 |
| Novartis Pharmaceuticals | Meals · 2025-01-07 | Cosentyx | $3 |
See earlier years (2024, 2023, 2022)
2024: $2,823
| Abbvie | Skyrizi | $718 | 34 payments
|
| Novartis Pharmaceuticals | Cosentyx | $271 | 15 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $259 | 9 payments
|
| Regeneron Healthcare Solutions | Dupixent | $257 | 7 payments
|
| Ucb | Bimzelx | $216 | 10 payments
|
| Incyte | Opzelura | $196 | 7 payments
|
| Janssen Biotech | Tremfya | $165 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Spevigo | $119 | 5 payments
|
| Lilly USA | Taltz | $106 | 5 payments
|
| LEO Pharma | Adbry | $96 | 5 payments
|
| Amgen | Otezla | $89 | 3 payments
|
| Arcutis Biotherapeutics | Zoryve | $84 | 4 payments
|
| Fresenius Kabi USA | Idacio | $73 | 3 payments
|
| Ortho Dermatologics a division of Bausch Health US | Siliq | $43 | 2 payments
|
| Galderma Laboratories L.P. | None | $38 | 1 payment
|
| Genzyme | Dupixent | $38 | 2 payments
|
| Kyowa Kirin | Poteligeo | $25 | 1 payment
|
| Pfizer | Cibinqo | $16 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $15 | 1 payment
|
2023: $1,685
| Abbvie | Skyrizi | $640 | 29 payments
|
| Amgen | Otezla | $175 | 6 payments
|
| Lilly USA | Taltz | $169 | 6 payments
|
| Sun Pharmaceutical Industries | Ilumya | $162 | 7 payments
|
| Novartis Pharmaceuticals | Cosentyx | $129 | 11 payments
|
| Janssen Biotech | Remicade | $104 | 5 payments
|
| Fresenius Kabi USA | Idacio | $52 | 2 payments
|
| Ucb | Bimzelx | $50 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $44 | 2 payments
|
| Pfizer | Eucrisa | $44 | 2 payments
|
| Incyte | Opzelura | $42 | 2 payments
|
| Dermavant Sciences | Vtama | $39 | 2 payments
|
| Genzyme | Dupixent | $35 | 1 payment
|
2022: $550
| Abbvie | Skyrizi | $288 | 12 payments
|
| Pfizer | Cibinqo | $72 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $55 | 2 payments
|
| Novartis Pharmaceuticals | Xolair | $33 | 2 payments
|
| Dermavant Sciences | Vtama | $28 | 2 payments
|
| Lilly USA | Taltz | $28 | 1 payment
|
| Genzyme | Dupixent | $26 | 1 payment
|
| Incyte | Opzelura | $19 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1093254674
- Licence
- CA 54213California C54213: Surrendered
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant, medical (363AM0700X)
- Mailing address
- 2725 Mendocino Ave, Santa Rosa, CA, 95403
- NPI first listed
- 2017-02-16
- NPI last updated
- 2022-05-05
- NPI record certified
- 2022-05-05
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 398 Boynton Ave, San Jose, CA, 95117